In-Med AI Launches Oncoshield CT Tool for Liver and Pancreatic Cancer Diagnosis
Written by Arushi Sharma
In-Med AI unveils Oncoshield, an AI-powered CT tool for liver and pancreatic cancer diagnosis. Oncoshield automatically detects lesions, analyzes volume and density, and aids treatment planning with high accuracy.
In-Med AI, a leading developer of AI/ML tools for healthcare analytics, has unveiled its latest innovation, the "Oncoshield" CT tool.
Tailored for clinical decision support in the diagnosis and treatment of liver and pancreatic cancers, Oncoshield promises to revolutionize patient care with its advanced capabilities.
The Oncoshield software automatically detects and quantifies lesions in the liver and pancreas from CT scans, offering invaluable insights for clinicians. With over 90% accuracy and rapid processing within minutes, it significantly enhances diagnostic capabilities, especially in surgical preparation.
Early detection of liver lesions is critical for prompt medical intervention and improved patient outcomes, and Oncoshield assists radiologists in precisely that. By providing quantitative assessment, volume calculation, and density analysis, the tool aids in treatment planning and monitoring, distinguishing between benign and malignant lesions.
Moreover, Oncoshield's insights aid surgeons in understanding lesion characteristics and making informed decisions regarding the best course of action for patients. By stratifying patients based on risk, it enables personalized treatment plans, thereby optimizing patient care.
Beyond reducing radiologist workload through automated analysis, Oncoshield facilitates longitudinal assessment of treatment effectiveness, empowering oncologists and hepatologists to make timely adjustments for better outcomes.
In addition to clinical applications, Oncoshield serves as a valuable tool for medical research and clinical trials, contributing to a deeper understanding of liver diseases and treatment outcomes.
The seamless integration of Oncoshield into clinical and radiology workflows ensures efficient prioritization of critical cases, with reports promptly delivered to decision-makers via various channels.
Rahim Pathan, Head of Development Center at In-Med, highlighted the company's commitment to innovation and transformative healthcare solutions, underscoring the importance of continuous advancement in the field.
Dr. Latha Poonamallee, Founder and CEO of In-Med AI, expressed enthusiasm for Oncoshield's potential to revolutionize patient care, emphasizing the company's mission to harness AI's potential for inclusive and innovative healthcare solutions.
With Oncoshield's launch, In-Med AI continues its legacy of pioneering transformative solutions in healthcare, following the success of its Neuroshield MRI Volumetry product targeting neurodegenerative conditions. This new milestone reinforces In-Med's commitment to expanding its multi-modal capabilities and delivering impactful solutions to the healthcare ecosystem.